Vela Laboratories receives GMP certificate

April 7, 2008 — /PRNewswire/ — VIENNA, AUSTRIA — Vela Laboratories announced today that it has received the GMP certificate for its analytical and quality control laboratories. “Good Manufacturing Practice” is a body of internationally accepted regulations set forth by European and American drug agencies. GMP compliance ensures that pharmaceuticals, active ingredients, and medical devices are produced and quality-controlled according to state-of-the-art standards.

“GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for Vela Labs to have reached the GMP certification just 18 months since its formation,” says Dr. Markus Fido, founder and CEO of Vela Laboratories. “Now that Vela Laboratories is GMP certified, its analytical services fully qualify to support clinical studies as well as regulatory submissions.”

“GMP certification is an important milestone for our analytical services business. Now we will start to consistently expand our analytical methods portfolio that we are offering to the pharmaceutical and biotech industry,” says Dr. Andreas Nechansky, founder and chief operating officer of Vela Laboratories.

“Having achieved GMP compliance enables Vela to develop its therapeutic anti-cancer antibodies in the shortest time possible and with the highest quality,” says Dr. Ralf Kircheis, founder and chief scientific officer of Vela Laboratories.

About Vela Laboratories

Vela Laboratories (Vela pharmazeutische Entwicklung und LaboranalytikGmbH) provides a broad portfolio of analytical methods for preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals. Additionally, the company develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. The company’s lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, it also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, grants from Austrian government agencies (AWS and ZIT/LISA), and through revenues generated by its analytical services business.



Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.